C3N-02234
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 67.77275838
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.550
- INTERFERON_GAMMA_RESPONSE+0.420
- IL6_JAK_STAT3_SIGNALING+0.340
- CHOLESTEROL_HOMEOSTASIS+0.290
- INFLAMMATORY_RESPONSE+0.230
- BILE_ACID_METABOLISM+0.220
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.220
- TNFA_SIGNALING_VIA_NFKB+0.190
- ANDROGEN_RESPONSE+0.180
- SPERMATOGENESIS+0.180
Top 10 suppressed
- ANGIOGENESIS-0.490
- HEDGEHOG_SIGNALING-0.490
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.480
- MYC_TARGETS_V2-0.440
- MYC_TARGETS_V1-0.400
- UNFOLDED_PROTEIN_RESPONSE-0.390
- APICAL_JUNCTION-0.310
- OXIDATIVE_PHOSPHORYLATION-0.280
- GLYCOLYSIS-0.270
- WNT_BETA_CATENIN_SIGNALING-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2208913 | — | — | 0.862 |
| 2 | TCGA-A8-A08I-01A-11R-A00Z-07 | — | C | 0.789 |
| 3 | 7d3b4d06-1249-4a85-a66a-387d4e2e2cb2 | — | — | 0.780 |
| 4 | SRR2932831 | — | — | 0.773 |
| 5 | ERR2208965 | — | — | 0.770 |
| 6 | 1f57edd1-3bc9-4eaf-8045-8984d5c7f148 | — | — | 0.757 |
| 7 | TCGA-EW-A1J5-01A-11R-A13Q-07 | — | B | 0.751 |
| 8 | 06ef2350-1dd1-46e9-a1ac-8fc731a6abc7 | — | — | 0.745 |
| 9 | TCGA-55-7995-01A-11R-2187-07 | — | cohortA1 | 0.743 |
| 10 | TCGA-NC-A5HJ-01A-11R-A26W-07 | — | cohortA1 | 0.743 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.550 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.420 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.340 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.290 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.230 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.220 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.220 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.190 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.180 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.180 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.170 | Idelalisib | — uncovered |
| COMPLEMENT | 0.160 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.160 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.150 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.100 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.080 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.060 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.050 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.050 | Inavolisib | — uncovered |